Catherine Wood's ARCT Position Overview
Catherine Wood (via Ark Investment Management LLC) currently holds 2.77 M shares of Arcturus Therapeutics Holdings Inc. (ARCT) worth $21.38 M, representing 0.17% of the portfolio. First purchased in 2019-Q2, this long-term strategic position has been held for 28 quarters.
Based on 13F filings, Catherine Wood has maintained a strategic position in ARCT, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2020, adding 1.46 M shares. Largest reduction occurred in Q1 2021, reducing 627,130 shares.
Analysis based on 13F filings available since 2013 Q2
Catherine Wood's Arcturus Therapeutics Holdings (ARCT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Arcturus Therapeutics Holdings (ARCT) Trades by Catherine Wood
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +158,419 | Add 6.07% | 2.77 M | $7.72 |
| Q4 2025 | +738,378 | Add 39.43% | 2.61 M | $6.13 |
| Q3 2025 | +157,681 | Add 9.19% | 1.87 M | $18.43 |
| Q2 2025 | -293,440 | Reduce 14.61% | 1.72 M | $13.01 |
| Q1 2025 | +74,629 | Add 3.86% | 2.01 M | $10.59 |
| Q4 2024 | -167,187 | Reduce 7.96% | 1.93 M | $16.97 |
| Q3 2024 | +136,074 | Add 6.93% | 2.1 M | $23.21 |
| Q2 2024 | +275,315 | Add 16.29% | 1.96 M | $24.35 |
| Q1 2024 | -358,038 | Reduce 17.48% | 1.69 M | $33.77 |
| Q4 2023 | +146,141 | Add 7.69% | 2.05 M | $31.53 |
| Q3 2023 | -5,450 | Reduce 0.29% | 1.9 M | $25.55 |
| Q2 2023 | -78,425 | Reduce 3.95% | 1.91 M | $28.68 |
| Q1 2023 | -27,008 | Reduce 1.34% | 1.99 M | $23.97 |
| Q4 2022 | -169,274 | Reduce 7.76% | 2.01 M | $16.96 |
| Q3 2022 | -122,048 | Reduce 5.30% | 2.18 M | $14.82 |
| Q2 2022 | -80,089 | Reduce 3.36% | 2.3 M | $19.88 |
| Q1 2022 | -88,790 | Reduce 3.59% | 2.38 M | $26.96 |
| Q4 2021 | -56,879 | Reduce 2.25% | 2.47 M | $37.01 |
| Q3 2021 | -355,173 | Reduce 12.31% | 2.53 M | $47.78 |
| Q2 2021 | -447,207 | Reduce 13.42% | 2.88 M | $33.84 |
| Q1 2021 | -627,130 | Reduce 15.84% | 3.33 M | $41.30 |
| Q4 2020 | +1.46 M | Add 58.62% | 3.96 M | $43.38 |
| Q3 2020 | +577,007 | Add 30.07% | 2.5 M | $42.90 |
| Q2 2020 | +354,378 | Add 22.65% | 1.92 M | $46.74 |
| Q1 2020 | +180,701 | Add 13.06% | 1.56 M | $13.59 |
| Q4 2019 | +109,343 | Add 8.58% | 1.38 M | $10.87 |
| Q3 2019 | +270,045 | Add 26.89% | 1.27 M | $10.27 |
| Q2 2019 | +1 M | New Buy | 1 M | $9.44 |
Catherine Wood's Arcturus Therapeutics Holdings Investment FAQs
Catherine Wood first purchased Arcturus Therapeutics Holdings Inc. (ARCT) in Q2 2019, acquiring 1,004,368 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Catherine Wood has held Arcturus Therapeutics Holdings Inc. (ARCT) for 28 quarters since Q2 2019.
Catherine Wood's largest addition to Arcturus Therapeutics Holdings Inc. (ARCT) was in Q4 2020, adding 3,959,019 shares worth $171.74 M.
According to the latest 13F filing for Q1 2026, Catherine Wood's firm, Ark Investment Management LLC, owns 2,769,518 shares of Arcturus Therapeutics Holdings Inc. (ARCT), valued at approximately $21.38 M.
As of the Q1 2026 filing, Arcturus Therapeutics Holdings Inc. (ARCT) represents approximately 0.17% of Catherine Wood's publicly disclosed stock portfolio, making it one of their key holdings.
Catherine Wood's peak holding in Arcturus Therapeutics Holdings Inc. (ARCT) was 3,959,019 shares, as reported at the end of Q4 2020.